A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Plain-language summary

This observational study looks at the use of Lorlatinib as a first-line treatment in Chinese adults with ALK-positive advanced or metastatic non-small cell lung cancer. Adults aged 18 and over with confirmed ALK-positive status who started first-line Lorlatinib treatment may be included. It is a study without a phase and is currently not recruiting but ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Pfizer

Intervention

Lorlatinib

Start date

5/18/2026

Estimated completion

6/30/2026

Countries

China

Related genes

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Age ≥18 years
2. Diagnosed with a/mNSCLC
3. Confirmed testing for ALK-positive
4. Initiated first-line lorlatinib treatment during the patient selection period, prior therapy such as adjuvant or neoadjuvant treatment are allowed.
5. A minimum lookback period of at least 3 months to establish a baseline period and ensure first-line use of cohort entry drug
6. Have at least 6 months of follow-up data available (early death or progression will be included)